AbbVie Inc.

- There is no mention of plans for new fundraising through debt or equity in the provided transcript. - AbbVie highlights strong financial health and ample financial capacity to pursue business development. - The company has reduced its adjusted net interest expense forecast by $100 million due to favorable debt issuance rates. - Capital allocation priorities focus on investing in the business, pursuing business development, and returning capital to shareholders via dividends. - No indications of issuing new equity or raising debt beyond existing financial strategies were stated.

- AbbVie announced several new manufacturing site constructions as part of a $100 billion commitment to U.S. R&D and capital investments over the next decade. - $1.4 billion investment to build a pharmaceutical manufacturing campus in North Carolina. - $380 million investment for two new plants in North Chicago. - These strategic investments aim to strengthen AbbVie’s ability to produce medical breakthroughs in immunology, neuroscience, oncology, and obesity. - AbbVie is investing at record levels in the business to support long-term growth and pipeline development. - The company maintains strong financial flexibility to pursue compelling business development and return capital to shareholders.

- AbbVie raised full-year adjusted EPS guidance to $14.08-$14.28, reflecting strong momentum. - Total net revenues expected at approximately $67.3 billion, up $300 million from prior forecast. - Skyrizi global revenues projected at $21.6 billion, up $100 million, driven by psoriatic and IBD growth. - Rinvoq global sales forecast at $10.2 billion, up $100 million with strong performance in rheumatoid and gastro indications. - Neuroscience segment revenues expected to reach $12.6 billion, up $100 million due to portfolio momentum. - Immunology and neuroscience are delivering high double-digit growth, many assets growing north of 20%. - Skyrizi and Rinvoq expected to exceed peak sell-side consensus forecasts. - Oncology pipeline assets and obesity programs contribute to growth outlook. - AbbVie plans ongoing business development to drive long-term growth, with strong financial capacity. - Emphasis on best-in-class efficacy and convenient dosing regimens to capture market share.

- AbbVie raised its full-year adjusted earnings per share (EPS) guidance to a range of $14.08 to $14.28, up by $0.12 from previous guidance. - First quarter adjusted EPS exceeded guidance by $0.07, coming in at $2.65. - Adjusted operating margin ratio is expected to be approximately 47.5% of sales for the full year, including a 1% unfavorable impact from acquired IP R&D expenses. - Full-year adjusted gross margin is forecasted above 84% of sales. - Adjusted R&D expense is projected at approximately $9.7 billion, and adjusted SG&A expense at approximately $14.2 billion. - Second-quarter adjusted operating margin ratio is anticipated around 50% with EPS guidance between $3.74 and $3.78. - AbbVie expects top-tier growth with significant contributions from key products like Skyrizi and Rinvoq, both projected to exceed sell-side peak consensus forecasts.

No information is provided regarding the same in the latest conference call.